In line with this, a phase III 3-arm trial is currently exploring the effectiveness of a triplet therapy with the BRAF inhibitor plus MEK inhibitor associated with the anti EGFR antibody CETUXIMAB in BRAFV600E mCRC, in the second or third-line setting (BEACON CRC NCT02928224) (23). Here, BRAF is linked to colorectal carcinoma.